---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical presentation - signs and symptoms. Topics: Urinary bleeding: visible or nonvisible haematuria, Lower urinary tract symptoms: irritative voiding symptoms with carcinoma in situ, Physical signs: no findings on examination, Cystoscopic signs: flat reddish or nonvisible carcinoma in situ, and 2 further topics. 6 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Urinary bleeding: visible or nonvisible haematuria

> “Haematuria is the most common finding in NMIBC. Visible haematuria was found to be associated with higher stage at diagnosis disease compared to nonvisible haematuria”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Bladder cancer typically presents with gross or microscopic hematuria.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

> “Bladder tumors can present with gross or microscopic hematuria, which is evaluated with cystoscopy and upper tract imaging depending on the degree of hematuria and risk of malignancy.”

Source: [Lenis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33201207/)

<a id="topic-2.2.1.6-2"></a>

### Lower urinary tract symptoms: irritative voiding symptoms with carcinoma in situ

> “Carcinoma in situ might be suspected in patients with lower urinary tract symptoms, especially irritative voiding symptoms.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Less commonly, patients may complain of urinary frequency, nocturia, and dysuria, symptoms that are more common in patients with carcinoma in situ.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.6-3"></a>

### Physical signs: no findings on examination

> “A focused urological examination is mandatory, although it does not reveal NMIBC.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.6-4"></a>

### Cystoscopic signs: flat reddish or nonvisible carcinoma in situ

> “Carcinoma in situ can present as a velvet-like, reddish area indistinguishable from inflammation, or it may not be visible at all.”
> “It can be missed or misinterpreted as an inflammatory lesion during cystoscopy if not biopsied.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.6-5"></a>

### Laboratory signs: malignant urine cytology with normal-looking mucosa

> “In patients with positive urine cytology (see Section 5.5) and normal-looking mucosa at cystoscopy, mapping biopsies are recommended”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.6-6"></a>

### Extravesical disease: upper urinary tract and prostatic urethral involvement

> “This risk becomes significant for both sites in high-risk tumours”
> “In a population-based study, 3.6% of patients with high-risk tumours (Ta G3 and CIS) developed upper urinary tract disease within ten years of diagnosis”
> “The incidence of CIS in the prostatic urethra was shown to be 11.7% in 128 males with T1 G3 UC”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Patients with upper urinary tract urothelial carcinomas may present with pain resulting from obstruction by the tumor.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
